Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:42:18.893Z.
Consensus retrieved: 2026-10-06T12:42:06.701Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:42:18.893Z.
Quote observation: 2026-10-06T14:40:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc00e8cb63dba40c56ed5fb80588e73c180b52fe93b8081d2416c5f575d95e45
Forward PE Ratio (N/A) = Dated Quote Price ($3.63) / Consensus Forward EPS ($-0.90)
FORWARD PE RATIO
N/A
Insight Molecular Diagnostics Inc.
Market Cap
$117.21M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $117.21M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.64M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.36M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | N/A |
| Genelux Corporation (GNLX)vs › | $114.34M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.74M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.17M | N/A |
| Cibus, Inc. (CBUS)vs › | $123.66M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.63, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.90 | $-0.91 – $-0.90 | 3 | n/m |
| 2027-12-31 | $-0.86 | $-0.90 – $-0.82 | 3 | n/m |
| 2028-12-31 | $-0.62 | $-0.80 – $-0.44 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
